360 related articles for article (PubMed ID: 22344548)
21. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X; Ma J; Wang K; Zhang H
Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
[TBL] [Abstract][Full Text] [Related]
22. [Therapy of chronic inflammatory bowel diseases].
Beglinger C
Ther Umsch; 1997 Nov; 54(11):649-53. PubMed ID: 9454368
[TBL] [Abstract][Full Text] [Related]
23. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
Giannini EG; Kane SV; Testa R; Savarino V
Dig Liver Dis; 2005 Oct; 37(10):723-31. PubMed ID: 16023905
[TBL] [Abstract][Full Text] [Related]
24. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
25. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
26. [Mesalazine old and new].
Mañosa M; Domènech E
Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():25-9. PubMed ID: 25443223
[TBL] [Abstract][Full Text] [Related]
27. Review article: aminosalicylates in inflammatory bowel disease.
Hanauer SB
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
[TBL] [Abstract][Full Text] [Related]
28. Mesalazine in inflammatory bowel disease: a trendy topic once again?
Iacucci M; de Silva S; Ghosh S
Can J Gastroenterol; 2010 Feb; 24(2):127-33. PubMed ID: 20151072
[TBL] [Abstract][Full Text] [Related]
29. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease.
Calviño J; Romero R; Pintos E; Losada E; Novoa D; Güimil D; Mardaras J; Sanchez-Guisande D
Clin Nephrol; 1998 Apr; 49(4):265-7. PubMed ID: 9582560
[TBL] [Abstract][Full Text] [Related]
30. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
Chan EP; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
[TBL] [Abstract][Full Text] [Related]
31. Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
Lakatos PL; Lakatos L
Pharmacol Res; 2008; 58(3-4):190-5. PubMed ID: 18801439
[TBL] [Abstract][Full Text] [Related]
32. Management of distal ulcerative colitis: frequently asked questions analysis.
James SL; Irving PM; Gearry RB; Gibson PR
Intern Med J; 2008 Feb; 38(2):114-9. PubMed ID: 18290827
[TBL] [Abstract][Full Text] [Related]
33. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
34. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
Ioffe AIu
Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
[TBL] [Abstract][Full Text] [Related]
35. What's new: innovative concepts in inflammatory bowel disease.
Sandborn WJ
Colorectal Dis; 2006 May; 8 Suppl 1():3-9. PubMed ID: 16594957
[TBL] [Abstract][Full Text] [Related]
36. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Sandborn WJ
J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
[TBL] [Abstract][Full Text] [Related]
37. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Lichtenstein GR; Kamm MA
Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
[TBL] [Abstract][Full Text] [Related]
38. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
[No Abstract] [Full Text] [Related]
39. Clinical pharmacokinetics of slow release mesalazine.
De Vos M
Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
[TBL] [Abstract][Full Text] [Related]
40. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
